Xcel Energy Inc. (XEL) Pops 2.59% for January 28

Equities Staff |

One of the S&P 500’s big winners for Thursday January 28 was Xcel Energy Inc. ($XEL) as the company’s stock climbed 2.59% to $37.63 on volume of 2.31 million shares.

The stock opened at $36.36 and saw an intraday low of $36.10 and an intraday high of $37.84. All told, the day saw a per-share gain of $0.95. The stock’s average daily volume of 3.56 million and 507.5 million shares outstanding. Xcel Energy Inc. now has a 50-day SMA is $35.70 and 200-day SMA is $34.10, and it has a 52-week high of $38.35 and a 52-week low of $31.76.

Xcel Energy Inc is a holding company engaged in the generation, purchase, transmission, distribution and sale of electricity and in the purchase, transportation, distribution and sale of natural gas.

Based out of Minneapolis, MN, Xcel Energy Inc. has 11,691 employees and, after today’s trading, reached a market cap of $19.1 billion. Its P/S ratio is n/a, P/B ratio is 1.81, and P/FCF ratio is 33.4.

For a complete fundamental analysis analysis of Xcel Energy Inc., check out Equities.com’s Stock Valuation Analysis report for XEL. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…